Novartis cuts price of Cosentyx after PVA negotiations
By Lee, Tak-Sun | translator Alice Kang
24.11.07 05:05:06
가나다라
0
Was applied ‘Type B’ of Price-Volume Agreement Scheme after being applied ‘Type A’ in 2021…affected by the company’s release of a new product
▲Cosentyx UnoReady Pen
The price of Novartis’s Cosentyx(secukinumab) is set to be reduced due to its increased use. This is because the National Health Insurance Service recently reached an agreement during Price-Volume Agreement negotiations with the company for Cosentyx.
According to industry sources on the 6th, the insurance price ceiling of Cosentyx was adjusted for the second time under the PVA system after 2021.
The affected products are the Cosentyx SensoReady Pen and Cosentyx UnoReady Pen.
Cosentyx was listed for reimbursement in Korea in August 2017. Currently reimbursed indications include ▲chronic severe plaque psoriasis, ▲active and progressive psoriatic arthritis,
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)